Press releases

Press release
Medivir makes strategic decision to focus proprietary hepatitis C R&D efforts exclusively on nucleotide-based polymerase inhibitors

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that it will focus its proprietary hepatitis C (HCV) research and development...

Read more
Press release
Medivir streamlines operations by divesting Cross Pharma, its parallel import business

Stockholm — Medivir AB (OMX: MVIR) today announced that the company has signed an agreement to sell its wholly owned subsidiary,...

Read more
Press release
Medivir recruits a new head of Commercial Operations

Stockholm — Medivir AB (OMX: MVIR) strengthens the executive management team by recruiting Henrik Krook as Executive VP Commercial. Henrik will...

Read more
Press release
Primary efficacy and safety data from four phase III Japanese studies of Simeprevir presented at The Japan Society of Hepatology

Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen Pharmaceutical R&D Ireland (Janssen) today announced primary efficacy and...

Read more
Press release
Medivir presents at the Jefferies Global Healthcare Conference

Medivir will participate in, and present at, the Jefferies 2013 Global Healthcare Conference in New York. Slides from the presentation will...

Read more
Press release
An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called...

Read more
Press release
Primary efficacy and safety findings from phase III study of Simeprevir in treatment-experienced patients demonstrate sustained virologic response

Stockholm, Sweden — Medivir AB (OMX: MVIR) reports that its partner Janssen R&D Ireland (Janssen) today announced primary efficacy and safety...

Read more
Press release
Positive results from a phase Ia study with MIV-711 for the treatment of skeletal disorders

Single doses of MIV-711 were safe and well tolerated in healthy subjects and displayed linear pharmacokinetics over the investigated dose range...

Read more
Press release
U.S. FDA grants priority review to Simeprevir for combination treatment of genotype 1 chronic hepatitis C

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the U.S. Food and Drug Administration (FDA) has granted Priority Review...

Read more
Press release
Resolutions at the annual general meeting in Medivir on 6 May 2013

Election of the board of directors and auditorThe annual general meeting in Medivir Aktiebolag (publ) on 6 May 2013 resolved, in...

Read more
Press release
Interim Report, 1 January – 31 March 2013*

Q1 2013 (January-March) Net turnover totalled SEK 282.6 million (SEK 137.9 m). The profit/loss after tax was SEK 77.6 million (SEK...

Read more
Press release
Webcast presentation of Simeprevir phase III clinical data

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Janssen R&D Ireland and Johnson & Johnson will provide a pre-recorded...

Read more